Sold as Prelay, Rezulin. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 2 applications for Troglitazone (sold as Prelay, Rezulin), first approved Jan 29, 1997, with 7 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jan 29, 1997 | PrelayNDA 20719 · New formulation or manufacturer | Sankyo | 9 | Discontinued |
| Jan 29, 1997 | RezulinNDA 20720 · New molecular entity | Pfizer Pharms | 11 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
